Alzamend Neuro, Inc. ALZN
We take great care to ensure that the data presented and summarized in this overview for Alzamend Neuro, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ALZN
Top Purchases
Top Sells
About ALZN
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Insider Transactions at ALZN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
3,566
-10.13%
|
$7,132
$2.33 P/Share
|
|
Sep 29
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
38,324
-52.13%
|
$76,648
$2.31 P/Share
|
|
Sep 26
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
37,738
-33.92%
|
$75,476
$2.31 P/Share
|
|
Sep 25
2025
|
Milton C Ault Iii |
BUY
Conversion of derivative security
|
Indirect |
100,000
+47.34%
|
$200,000
$2.32 P/Share
|
|
Sep 25
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
14,628
-56.52%
|
$29,256
$2.31 P/Share
|
|
Sep 24
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
39,140
-60.2%
|
$78,280
$2.31 P/Share
|
|
Sep 23
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
43,238
-39.94%
|
$86,476
$2.38 P/Share
|
|
Sep 22
2025
|
Milton C Ault Iii |
BUY
Conversion of derivative security
|
Indirect |
100,000
+48.02%
|
$200,000
$2.32 P/Share
|
|
Sep 19
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
77,009
-90.31%
|
$154,018
$2.35 P/Share
|
|
Sep 18
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
20,870
-19.66%
|
$41,740
$2.47 P/Share
|
|
Sep 17
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
2,121
-1.96%
|
$4,242
$2.45 P/Share
|
|
Sep 17
2025
|
Milton C Ault Iii |
BUY
Conversion of derivative security
|
Indirect |
100,000
+48.02%
|
$200,000
$2.32 P/Share
|
|
Jul 31
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
100,000
-92.37%
|
$200,000
$2.22 P/Share
|
|
Jul 30
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
29,449
-21.38%
|
$58,898
$2.51 P/Share
|
|
Jul 30
2025
|
Milton C Ault Iii |
BUY
Conversion of derivative security
|
Indirect |
100,000
+42.07%
|
$200,000
$2.32 P/Share
|
|
Jul 28
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
8,311
-18.06%
|
$16,622
$2.68 P/Share
|
|
Jul 25
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
36,532
-44.25%
|
$73,064
$2.9 P/Share
|
|
Jul 24
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
9,621
-10.44%
|
$19,242
$2.93 P/Share
|
|
Jul 23
2025
|
Milton C Ault Iii |
SELL
Open market or private sale
|
Indirect |
59,516
-39.24%
|
$119,032
$2.95 P/Share
|
|
Jul 23
2025
|
Milton C Ault Iii |
BUY
Conversion of derivative security
|
Indirect |
143,429
+48.6%
|
$286,858
$2.32 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 543K shares |
|---|---|
| Open market or private purchase | 26.3K shares |
| Exercise of conversion of derivative security | 10K shares |
| Open market or private sale | 521K shares |
|---|